Pharmaceutical Executive
Analysts say Times' accusatory articles on Zyprexa are nothing to get excited about.
Pharmaceutical Executive-12-20-2006
Pharmaceutical Executive
FDA's revisions to guidelines on expanding access to experimental drugs intensify an already murky issue for pharma.
Pharmaceutical Executive
At its annual pipeline debut, the company introduced its own CETP-inhibitor--with doubts.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
